FDA approves Barr subsidiary’s generic form of Pfizer’s Camptosar

MONTVALE, N.J. Food and Drug Administration has approved a generic version of Pfizer’s injected drug Camptosar, the drug’s manufacturer announced Monday.

PLIVA  Lachema, a subsidiary of Barr Pharmaceuticals, will market the drug in vials containing 20 mg per milliliter, 40 mg per two milliliters and 100 mg per five milliliters.

The drug, known generically as irinotecan hydrochloride, is used to treat metastatic carcinoma of the colon and rectum and brings Barr’s portfolio of injectables to nine products.